Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses (2016 - 2026)

Anika Therapeutics has reported Accumulated Expenses over the past 17 years, most recently at $14.6 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 146.0% to $14.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.6 million through Mar 2026, up 146.0% year-over-year, with the annual reading at $15.9 million for FY2025, 16.95% up from the prior year.
  • Accumulated Expenses was $14.6 million for Q1 2026 at Anika Therapeutics, down from $15.9 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $19.7 million in Q1 2023 and troughed at $5.9 million in Q1 2025.
  • The 5-year median for Accumulated Expenses is $11.2 million (2022), against an average of $11.7 million.
  • Year-over-year, Accumulated Expenses surged 164.78% in 2023 and then crashed 56.47% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $11.3 million in 2022, then rose by 24.44% to $14.1 million in 2023, then decreased by 3.55% to $13.6 million in 2024, then increased by 16.95% to $15.9 million in 2025, then decreased by 7.81% to $14.6 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Accumulated Expenses are $14.6 million (Q1 2026), $15.9 million (Q4 2025), and $14.4 million (Q3 2025).